162 related articles for article (PubMed ID: 1464164)
1. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.
Wilkinson TJ; Robinson BA; Begg EJ; Duffull SB; Ravenscroft PJ; Schneider JJ
Cancer Chemother Pharmacol; 1992; 31(3):251-4. PubMed ID: 1464164
[TBL] [Abstract][Full Text] [Related]
2. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
4. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity.
Babul N; Darke AC
Clin Pharmacol Ther; 1993 Sep; 54(3):286-92. PubMed ID: 8375123
[TBL] [Abstract][Full Text] [Related]
5. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.
Poulain P; Hoskin PJ; Hanks GW; A-Omar O; Walker VA; Johnston A; Turner P; Aherne GW
Br J Anaesth; 1988 Nov; 61(5):569-74. PubMed ID: 3207527
[TBL] [Abstract][Full Text] [Related]
8. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
9. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.
van Dongen RT; Crul BJ; Koopman-Kimenai PM; Vree TB
Br J Clin Pharmacol; 1994 Sep; 38(3):271-3. PubMed ID: 7826830
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
12. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
[TBL] [Abstract][Full Text] [Related]
13. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
Klepstad P; Kaasa S; Borchgrevink PC
Eur J Clin Pharmacol; 2000 Jan; 55(10):713-9. PubMed ID: 10663448
[TBL] [Abstract][Full Text] [Related]
14. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
[TBL] [Abstract][Full Text] [Related]
15. Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose.
Lundeberg S; Beck O; Olsson GL; Boreus LO
Acta Anaesthesiol Scand; 1996 Apr; 40(4):445-51. PubMed ID: 8738689
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.
Brokjær A; Kreilgaard M; Olesen AE; Simonsson US; Christrup LL; Dahan A; Drewes AM
Eur J Pharm Sci; 2015 Feb; 68():78-86. PubMed ID: 25486331
[TBL] [Abstract][Full Text] [Related]
17. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML
Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.
Hunt A; Joel S; Dick G; Goldman A
J Pediatr; 1999 Jul; 135(1):47-55. PubMed ID: 10393603
[TBL] [Abstract][Full Text] [Related]
19. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
